Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L Reagan

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|February 14, 2018
Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual DiseaseThomas A Ollila, Adam J Olszewski, James N Butera, et al.
The Oncologist|March 21, 2023
Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group StudyAri Pelcovits, Peter Barth, John L Reagan, et al.
Leukemia Research|January 31, 2012
Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studiesJorge J Castillo, John L Reagan, Randall R Ingham, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2011
Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHLJohn L Reagan, Alan Rosmarin, James N Butera, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2004
Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cellsGudrun Ratzinger, Jan Baggers, Maria A de Cos, et al.
Rhode Island Medical Journal (2013)|October 2, 2020
Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical RecordAdam S Zayac, Ross W Hilliard, Adam J Olszewski, et al.
Journal of Translational Medicine|June 21, 2013
Cellular immunotherapy for refractory hematological malignanciesJohn L Reagan, Loren D Fast, Howard Safran, et al.
Journal of Cellular Physiology|January 16, 2019
Potential biomarkers to detect traumatic brain injury by the profiling of salivary extracellular vesiclesYan Cheng, Mandy Pereira, Neha Raukar, et al.
Neural Regeneration Research|October 23, 2019
Inflammation-related gene expression profiles of salivary extracellular vesicles in patients with head traumaYan Cheng, Mandy Pereira, Neha P Raukar, et al.
Journal of Oncology Practice|February 25, 2016
Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer ProgramKalyan C Mantripragada, Adam J Olszewski, Andrew Schumacher, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|February 14, 2018
Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual DiseaseThomas A Ollila, Adam J Olszewski, James N Butera, et al.
The Oncologist|March 21, 2023
Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group StudyAri Pelcovits, Peter Barth, John L Reagan, et al.
Leukemia Research|January 31, 2012
Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studiesJorge J Castillo, John L Reagan, Randall R Ingham, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2011
Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHLJohn L Reagan, Alan Rosmarin, James N Butera, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2004
Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cellsGudrun Ratzinger, Jan Baggers, Maria A de Cos, et al.
Rhode Island Medical Journal (2013)|October 2, 2020
Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical RecordAdam S Zayac, Ross W Hilliard, Adam J Olszewski, et al.
Journal of Translational Medicine|June 21, 2013
Cellular immunotherapy for refractory hematological malignanciesJohn L Reagan, Loren D Fast, Howard Safran, et al.
Journal of Cellular Physiology|January 16, 2019
Potential biomarkers to detect traumatic brain injury by the profiling of salivary extracellular vesiclesYan Cheng, Mandy Pereira, Neha Raukar, et al.
Neural Regeneration Research|October 23, 2019
Inflammation-related gene expression profiles of salivary extracellular vesicles in patients with head traumaYan Cheng, Mandy Pereira, Neha P Raukar, et al.
Journal of Oncology Practice|February 25, 2016
Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer ProgramKalyan C Mantripragada, Adam J Olszewski, Andrew Schumacher, et al.
Pageof 8